본문으로 건너뛰기
← 뒤로

Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.

증례보고 1/5 보강
Urology case reports 📖 저널 OA 100% 2022: 2/2 OA 2023: 1/1 OA 2025: 19/19 OA 2026: 14/14 OA 2022~2026 2025 Vol.63() p. 103245
Retraction 확인
출처

Nagaya N, Hokota K, Hirose K, Yanai J, Morino J, Nagashima Y

📝 환자 설명용 한 줄

Prostate cancer with bone marrow carcinomatosis is rare and has a poor prognosis.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Nagaya N, Hokota K, et al. (2025). Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.. Urology case reports, 63, 103245. https://doi.org/10.1016/j.eucr.2025.103245
MLA Nagaya N, et al.. "Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.." Urology case reports, vol. 63, 2025, pp. 103245.
PMID 41142191 ↗

Abstract

Prostate cancer with bone marrow carcinomatosis is rare and has a poor prognosis. A 68-year-old man with severe thrombocytopenia was diagnosed with prostate cancer based on MRI and bone marrow biopsy findings. Initial treatment with a GnRH antagonist and apalutamide showed limited efficacy for thrombocytopenia despite PSA response, prompting the addition of carboplatin and etoposide (CE) chemotherapy. Thrombocytopenia resolved following CE chemotherapy. After four CE cycles, ProGRP stabilized and PSA decreased significantly. Tumor control was maintained for a year with hormonal therapy. This case underscores the need for early, multidisciplinary treatment in histologically heterogeneous prostate cancer.

같은 제1저자의 인용 많은 논문 (1)

🟢 PMC 전문 열기